Jefferies Starts Zynerba Pharmaceuticals (ZYNE) at Buy
Get Alerts ZYNE Hot Sheet
Rating Summary:
4 Buy, 7 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Jefferies initiates coverage on Zynerba Pharmaceuticals (NASDAQ: ZYNE) with a Buy rating and a price target of $33.00.
Analyst Biren Amin commented, "ZYNE is poised to become a leader in synthetic cannabinoid therapies with a focus on transdermal delivery. Its lead candidate is ZYN002, a permeation-enhanced CBD gel delivered through a transdermal patch for refractory epilepsy. Delivering CBD through the skin could lead to an improved safety profile over oral formulations. ZYNE is set to begin a PI trial in H2'15."
For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.
Shares of Zynerba Pharmaceuticals closed at $27.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Starts Grindr (GRND) at Buy
- Barclays Reinstates LondonMetric Property PLC (LMP:LN) (LNSPF) at Overweight
- William Blair Starts Solid Biosciences (SLDB) at Outperform, 'success in any of programs alone should provide severalfold upside from Solid’s current valuation'
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!